A Phase 3 interventional study of Zoledronic acid and Letrozole in Bone Loss and Breast Cancer, sponsored by Novartis Pharmaceuticals. Completed at 106 sites in 28 countries. Open to female participants. Per ClinicalTrials.gov, last updated 2012-04-16.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic — 1 open to participants now, 1 under way, none of them phase 3. Zoledronic Acid · Bone Diseases, Metabolic.
Among the 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic, this one is the 2nd largest by enrollment, is one of 5 that started in 2003, is one of 9 in phase 3, and was the 11th registered.
662 studies on the registry are indexed under Bone Diseases, Metabolic; 94 are open to participants now.
Browse Bone Diseases, Metabolic studies →1 of the 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic is open now, in 1 country. Recruiting first, the newest first:
Hadassah Medical Organization · Sites in Israel
Ages 18+
By country, each count listing its studies:
Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 64 Bone Diseases, Metabolic studies recruiting now, 28 (44%) set no upper age limit and 28 (44%) stop at 75 or younger; 12 take children under 18; 22 take healthy volunteers.
This study: female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 9 · Phase 4 4
First in 2002; this study’s year is marked. 5 started in 2003.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,065 is above the median of 60 across 509 interventional studies indexed under Bone Diseases, Metabolic.
Median enrollment 135 across the 25 interventional studies. Of the 23 that completed or were terminated, 13 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
11 studies in Bone Diseases, Metabolic by Novartis: none open now, none under way, none of them phase 3. Of 11 finished, 3 (27%) have results posted.
Among the 11 studies in Bone Diseases, Metabolic by Novartis, this one is the 2nd largest by enrollment, is one of 3 that started in 2003, is one of 7 in phase 3, and was the 10th registered.
Novartis’s Bone Diseases, Metabolic studies by the year they started, since 2000.
None of the studies under way reaches primary completion within a year.
Among the 25 studies testing Zoledronic Acid in Bone Diseases, Metabolic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 11 in Bone Diseases, Metabolic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Post-menopausal breast cancer patients will receive letrozole 2.5 mg daily for the treatment of breast cancer and will be randomized to a treatment group to receive either upfront zoledronic acid 4 mg IV 15-minute infusion every 6 months or delayed start zoledronic acid 4 mg IV 15-minute infusion every 6 months. Delayed start zoledronic acid will be initiated when either the Bone Mineral Density T-score is below -2 Standard Deviations at either the lumbar spine or hip or any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the month 36 scheduled visit. Letrozole 2.5 mg will be given daily for 5 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
Other protocol-defined exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months for 5 years beginning on Day 1. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
Drug: Zoledronic acid · Drug: Letrozole
Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months beginning when one of the following occurred: BMD T-score \<= -2.0 SD at either the lumbar spine or total hip, any clinical fracture unrelated to trauma or an asymptomatic fracture discovered at the Month 36 visit. All participants took Letrozole tablets 2.5 mg/day for 5 years beginning on Day 1.
Drug: Zoledronic acid · Drug: Letrozole
Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
Also known as: ZOL446, Zometa®
Letrozole tablets 2.5 mg/day taken orally for 5 years.
Also known as: Femara®
Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).
Time frame: Baseline, 12 months
Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)
Time frame: Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.
Percentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)
Time frame: Baseline, 5 years.
Percentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)
Time frame: Baseline, 12 months. Baseline, 2 years. Baseline, 3 years. Baseline, 4 years. Baseline, 5 years.
Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline
At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.
Time frame: Baseline,3 years
| Milestone | Zoledronic Acid 4 mg Upfront | Zoledronic Acid 4 mg Delayed |
|---|---|---|
| Started | 532 | 533 |
| Completed | 408 | 398 |
| Not completed | 124 | 135 |
| Withdrew: Adverse event | 46 | 42 |
| Withdrew: Lack of efficacy | 29 | 41 |
| Withdrew: Protocol violation | 7 | 8 |
| Withdrew: Withdrawal by subject | 22 | 19 |
| Withdrew: Lost to follow-up | 0 | 5 |
| Withdrew: Abnormal laboratory results | 2 | 0 |
| Withdrew: Abnormal test procedure results | 6 | 11 |
| Withdrew: No longer required study drug | 1 | 1 |
| Withdrew: Administrative problems | 5 | 2 |
| Withdrew: Death | 6 | 6 |
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).
| Percentage change in BMD | Zoledronic Acid 4 mg Upfront | Zoledronic Acid 4 mg Delayed |
|---|---|---|
| Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy. | 2.208 ± 3.4194 | -3.617 ± 4.2151 |
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)
| Percentage change in BMD | Zolendronic Acid 4 mg Upfront | Zolendronic Acid 4 mg Delayed |
|---|---|---|
| At 2 years (n=339,343) | 3.463 ± 4.2691 | -4.601 ± 5.5273 |
| At 3 years (n=313,311) | 3.730 ± 4.884 | -4.871 ± 6.271 |
| At 4 years (n=290,294) | 3.782 ± 5.7300 | -5.154 ± 7.1079 |
| At 5 years (n=264,264) | 4.308 ± 6.0242 | -5.414 ± 7.6185 |
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)
| Percentage change in BMD | Zolendronic Acid 4 mg Upfront | Zolendronic Acid 4 mg Delayed |
|---|---|---|
| At 12 months (n=360,369) | 2.128 ± 3.2106 | -3603 ± 4.1808 |
| At 2 years (n=339,343) | 3.300 ± 4.0700 | -4.521 ± 5.2624 |
| At 3 years (n=313,311) | 3.521 ± 4.5936 | -4.869 ± 6.0310 |
| At 4 years (n=290,294) | 3.529 ± 5.5410 | -5.148 ± 6.8803 |
| At 5 years (n=264,264) | 3.898 ± 5.7995 | -5.427 ± 7.4818 |
Bone Mineral Density (g/cm\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)
| Percentage change in BMD | Zolendronic Acid 4 mg Upfront | Zolendronic Acid 4 mg Delayed |
|---|---|---|
| At 12 months (n=419,434) | 1.222 ± 2.3257 | -2.239 ± 3.3614 |
| At 2 years (n=394,393) | 1.649 ± 2.7333 | -2.990 ± 4.4318 |
| At 3 years (n=376,365) | 1.754 ± 3.1375 | -3.302 ± 4.8942 |
| At 4 years (n=336,349) | 1.716 ± 3.5228 | -3.922 ± 5.6505 |
| At 5 years (n=306,314) | 1.615 ± 3.7490 | -4.162 ± 6.0270 |
At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.
| Percentage of Participants | Zoledronic Acid 4 mg Upfront | Zoledronic Acid 4 mg Delayed |
|---|---|---|
| Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline | 0.6 | 1.5 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoledronic Acid 4mg Upfront | — | 133/525 (25.3%) | 477/525 (90.9%) |
| Zolendronic Acid 4mg Delayed | — | 124/535 (23.2%) | 486/535 (90.8%) |
| Event | Zoledronic Acid 4mg Upfront | Zolendronic Acid 4mg Delayed |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 4/525 | 10/535 |
| FallInjury, poisoning and procedural complications | 7/525 | 7/535 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 5/525 | 7/535 |
| PyrexiaGeneral disorders | 5/525 | 3/535 |
| Urinary tract infectionInfections and infestations | 4/525 | 1/535 |
| OsteonecrosisMusculoskeletal and connective tissue disorders | 4/525 | 1/535 |
| Atrial fibrillationCardiac disorders | 1/525 | 4/535 |
| Chest painGeneral disorders | 2/525 | 4/535 |
| PneumoniaInfections and infestations | 0/525 | 4/535 |
| Angina pectorisCardiac disorders | 3/525 | 2/535 |
| Event | Zoledronic Acid 4mg Upfront | Zolendronic Acid 4mg Delayed |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 256/525 | 251/535 |
| Hot flushVascular disorders | 152/525 | 163/535 |
| Bone painMusculoskeletal and connective tissue disorders | 97/525 | 64/535 |
| FatigueGeneral disorders | 93/525 | 95/535 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 69/525 | 80/535 |
| Back painMusculoskeletal and connective tissue disorders | 78/525 | 78/535 |
| PyrexiaGeneral disorders | 76/525 | 17/535 |
| HeadacheNervous system disorders | 75/525 | 63/535 |
| MyalgiaMusculoskeletal and connective tissue disorders | 68/525 | 71/535 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 58/525 | 60/535 |
| Age Continuous(Years) | Zoledronic Acid 4 mg Upfront | Zoledronic Acid 4 mg Delayed | Total |
|---|---|---|---|
| Median | 57 ± (36-87) | 58 ± (37-81) | 57 (36 to 87) |
| Sex: Female, Male(Participants) | Zoledronic Acid 4 mg Upfront | Zoledronic Acid 4 mg Delayed | Total |
|---|---|---|---|
| Female | 532 | 533 | 1065 |
| Male | 0 | 0 | 0 |
Showing the first 100 of 106 sites across 28 countries. Choose a country and city above to see the rest.
The record gives a start of May 2003, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zoledronic Acid · Letrozole